TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25833781

Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 12-month weight loss intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Changes in percentage body fat and plasma glucose concentrations
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Changes in dietary measures (vegetable, protein, total caloric intake)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intake of fruit
Number of subjects: 24
Study: 23158966

Group type: EXPERIMENTAL
Intervention: Real cervical manipulation (RM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham cervical manipulation (SM)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both RM and SM
Number of subjects: 64
Study: 21122419

Group type: EXPERIMENTAL
Intervention: NP/GP scheme synchronization chemotherapy combined with (125)I seed implantation brachytherapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: NP/GP scheme chemotherapy
Number of subjects: 76
Study: 19028251

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual contact intervention (MCI)
Number of subjects: 10
Study: 15717462

Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg x kg(‐1) bolus before incision, followed by continuous infusion of 1 mg x kg(‐1) x hr(‐1) during surgery)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no ketamine administration)
Number of subjects: 16
Study: 12501020

Group type: EXPERIMENTAL
Intervention: Adenosine and 20‐40 W bicycle exercise (stress study)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Rest study
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Weight increase
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Correlation with patient weight
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Injection activity adjustment
Number of subjects: 64
Study: 10643362

Group type: EXPERIMENTAL
Intervention: Sprotte G24 needle
Number of subjects: 197

Group type: COMPARATOR
Intervention: Spinocan G27 needle
Number of subjects: 197

Group type: COMPARATOR
Intervention: Atraucan G26 needle
Number of subjects: 197
Study: 8877156

Group type: EXPERIMENTAL
Intervention: Oral cetirizine (15 mg twice daily for 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (single dose 10 min prior to allergen challenge)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled beclomethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1846253

Group type: EXPERIMENTAL
Intervention: CsA/P
Number of subjects: 128

Group type: COMPARATOR
Intervention: CsA/Aza/P
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Aza/P
Number of subjects: 128
Study: 6469425

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Acebutolol (600 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study: 31188064

Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADC ratios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhancement ratios (ERs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ADC ratio and ER
Number of subjects: 0
Study: 30004560

Group type: EXPERIMENTAL
Intervention: Percutaneous balloon kyphoplasty (PKP)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 161
Study: 26398965

Group type: EXPERIMENTAL
Intervention: Loading perturbation (known)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Unloading perturbation (known)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Randomized loading/unloading perturbation (unknown)
Number of subjects: 17
Study: 23944632

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Statins (Atorvastatin and Rosuvastatin)
Number of subjects: 60
Study: 23131370

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (four one-hour sessions every two weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no massages during the control period)
Number of subjects: 16
Study: 20679528

Group type: EXPERIMENTAL
Intervention: Imatinib (STI571)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCR‐ABL transcripts > 10% at 6 months and > 1% at 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete cytogenetic response but not MMR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major molecular response (MMR) at 18 months
Number of subjects: 0
Study: 17351083

Group type: EXPERIMENTAL
Intervention: Computerized tracking training (track group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Movement training (move group)
Number of subjects: 20
Study: 16461248

Group type: EXPERIMENTAL
Intervention: Inhalation of 2 mL tea catechin extract solution (3.7 mg/mL catechins, 43% epigallocatechin gallate) 3 times daily for 7 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 72
Study: 15247119

Group type: EXPERIMENTAL
Intervention: Exercise intervention (45 minutes, 5 days per week of moderate intensity sports/recreational exercise)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 173
Study: 10716463

Group type: EXPERIMENTAL
Intervention: Directional Coronary Atherectomy (DCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 0
Study: 8958019

Group type: EXPERIMENTAL
Intervention: Mandibular BMD measurement (DXA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Symphysis BMD measurement (DXA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ramus BMD measurement (DXA)
Number of subjects: 40
Study: 1547962

Group type: EXPERIMENTAL
Intervention: tobramycin (15 mg/ml) in low-molecular-weight hyaluronic acid applied at 1 drop/h
Number of subjects: 26

Group type: COMPARATOR
Intervention: tobramycin (15 mg/ml) in saline applied at 1 drop/h
Number of subjects: 26
Study: 3873582

Group type: EXPERIMENTAL
Intervention: Oxygenated crystalloid solution
Number of subjects: 151

Group type: COMPARATOR
Intervention: Oxygenated solution
Number of subjects: 151
Study: 30612946

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-dose testosterone (about 1 mg/kg bodyweight) intramuscular injections every 4 weeks for 6 months
Number of subjects: 30
Study: 26989837

Group type: EXPERIMENTAL
Intervention: State insurance mandates requiring insurance plans to cover Pap tests
Number of subjects: 600000

Group type: COMPARATOR
Intervention: No state insurance mandate
Number of subjects: 600000
Study: 26537879

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard adhesive gauze dressing
Number of subjects: 108
Study: 23327869

Group type: EXPERIMENTAL
Intervention: Etoposide plus oxaliplatin (EO)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 71
Study: 21490523

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (0.25% levobupivacaine and 30 μg/kg morphine)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Paravertebral block (0.5% levobupivacaine and 30 μg/kg morphine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Paravertebral block
Number of subjects: 32
Study: 19679747

Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (1 g/day for 7-16 days)
Number of subjects: 30
Study: 17343724

Group type: EXPERIMENTAL
Intervention: Mobile Cardiac Outpatient Telemetry (MCOT)
Number of subjects: 122
Study: 15010071

Group type: EXPERIMENTAL
Intervention: Chemotherapy patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chemotherapy patients with elevated PAI-1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (orchidectomy only and healthy men)
Number of subjects: 90
Study: 11220813

Group type: EXPERIMENTAL
Intervention: Home environmental intervention (5 90-min home visits by occupational therapists)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Home environmental intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 171
Study: 9670603

Group type: EXPERIMENTAL
Intervention: CARL therapy program (computerized exposure therapy)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Alprazolam (placebo-controlled)
Number of subjects: 9
Study: 7873699

Group type: EXPERIMENTAL
Intervention: CS+ (sherbet sweet/white noise) paired with epinephrine injection (0.2 mg subcutaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CS- (herbal sweet/auditory stimulus)
Number of subjects: 0
Study: 3068191

Group type: EXPERIMENTAL
Intervention: Multiple logistic function model for preoperative assessment
Number of subjects: 8630

Group type: COMPARATOR
Intervention: Control group (group B, 2590 patients)
Number of subjects: 8630
Study: 31084532

Group type: EXPERIMENTAL
Intervention: Type II resin‐modified glass ionomer (RMGI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no box elevation procedure)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Type II glass ionomer (GI)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Resin‐based composite (RBC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bulk‐fill (BF) resin‐based composite
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups (RMGI, RBC, BF)
Number of subjects: 75
Study: 30526194

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (LTAD; 28 months)
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Short-term androgen deprivation (AD; 4 months)
Number of subjects: 1520
Study: 28164268

Group type: EXPERIMENTAL
Intervention: Supraclavicular block with 20 ml of 0.375% ropivacaine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Interscalene block with 20 ml of 0.375% ropivacaine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Number of subjects: 49

Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 49
Study: 25979871

Group type: EXPERIMENTAL
Intervention: Smoking reduction (biologically validated prolonged reducers)
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 2066
Study: 22556209

Group type: EXPERIMENTAL
Intervention: Daily feeding supplementation with a multispecies probiotic (1 g per day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Regular feedings with nothing added (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined risk of NEC or death for the study group
Number of subjects: 150
Study: 21632815

Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg, single sc injection)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 18823693

Group type: EXPERIMENTAL
Intervention: Immediate endocrine treatment (ET) consisting of a depot luteinising hormone-releasing hormone (LHRH) agonist and 1 month of an anti-androgen or surgical castration.
Number of subjects: 234

Group type: COMPARATOR
Intervention: Delayed endocrine treatment (ET) consisting of a depot luteinising hormone-releasing hormone (LHRH) agonist and 1 month of an anti-androgen or surgical castration.
Number of subjects: 234

Group type: COMPARATOR
Intervention: Delayed endocrine treatment (ET)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Immediate endocrine treatment (ET)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both immediate and delayed ET
Number of subjects: 234
Study: 17167925

Group type: EXPERIMENTAL
Intervention: Tipranavir + ritonavir
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Other protease inhibitors
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Tipranavir + ritonavir with enfuvirtide
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Tipranavir
Number of subjects: 1159
Study: 15192250

Group type: EXPERIMENTAL
Intervention: Trunk restraint during reach-to-grasp training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (verbal instruction not to move trunk)
Number of subjects: 28
Study: 14516301

Group type: EXPERIMENTAL
Intervention: Educational intervention with monthly audit sessions and outcome feedback for malaria treatment.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Educational intervention with monthly audit sessions and outcome feedback for diarrhoea treatment.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Educational intervention with monthly audit sessions and outcome feedback for pneumonia treatment.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 24
Study: 11079651

Group type: EXPERIMENTAL
Intervention: Orbufiban 30 mg, 40 mg, or 50 mg twice daily or 50 mg once daily
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Orbufiban
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 8932852

Group type: EXPERIMENTAL
Intervention: Hib-diphtheria toxoid conjugate vaccine (PRP-D) at 6 months and pneumococcal polysaccharide vaccine (Pnc PS) at 8 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (Pnc PS) at 18 months and Hib-diphtheria toxoid conjugate vaccine (PRP-D) at 20 months
Number of subjects: 45
Study: 1446399

Group type: EXPERIMENTAL
Intervention: Propofol 2.3 mg/kgr
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopental 4.4 mg/kgr
Number of subjects: 20
Study: 3997307

Group type: EXPERIMENTAL
Intervention: Carbamazepine tablets with rapid absorption
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbamazepine tablets with slow absorption
Number of subjects: 9

Group type: COMPARATOR
Intervention: All carbamazepine tablets
Number of subjects: 9
Study: 30368036

Group type: EXPERIMENTAL
Intervention: 90-minute de-escalation curriculum for pediatric residents
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study: 29370819

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 μg
Number of subjects: 1055

Group type: COMPARATOR
Intervention: FF/VI + UMEC 100/25 μg + 62.5 μg
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 1055

Group type: COMPARATOR
Intervention: FF/VI + UMEC
Number of subjects: 1055
Study: 25724020

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (4 personalized positive psychology exercises)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control condition (writing about life details for 8 weeks)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 96
Study: 24828020

Group type: EXPERIMENTAL
Intervention: RO-151 200 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: RO-838 200 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: RO-151 5 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: RO-838 50 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: RO-838
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: RO-151
Number of subjects: 109
Study: 22841581

Group type: EXPERIMENTAL
Intervention: 2.5 ppm fluoride in milk
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5.0 ppm fluoride in milk
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0 ppm fluoride in milk (control)
Number of subjects: 23
Study: 20207347

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 18757193

Group type: EXPERIMENTAL
Intervention: 16 Gy boost dose
Number of subjects: 5178

Group type: COMPARATOR
Intervention: No boost
Number of subjects: 5178

Group type: EXPERIMENTAL
Intervention: Boost arm with post-operative breast oedema or haematoma
Number of subjects: 5178

Group type: EXPERIMENTAL
Intervention: Boost arm with WBI given with >6 MV photons
Number of subjects: 5178

Group type: EXPERIMENTAL
Intervention: Increasing maximum whole breast irradiation (WBI) dose
Number of subjects: 5178

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy
Number of subjects: 5178

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5178
Study: 15638820

Group type: EXPERIMENTAL
Intervention: 100% fish oil (FO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 100% rapeseed oil (RO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 50% fish oil / 50% rapeseed oil (FO/RO)
Number of subjects: 60
Study: 12050494

Group type: EXPERIMENTAL
Intervention: Fluorescence diagnosis
Number of subjects: 301

Group type: COMPARATOR
Intervention: White light
Number of subjects: 301
Study: 10065579

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control subjects (normal weight)
Number of subjects: 11
Study: 7727181

Group type: EXPERIMENTAL
Intervention: enalapril plus salicylate
Number of subjects: 20

Group type: COMPARATOR
Intervention: enalapril plus placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: salicylate
Number of subjects: 20
Study: 2034456

Group type: EXPERIMENTAL
Intervention: Hydrogel lenses with varying water content (36.5% to 85%)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydrogel lenses with higher water content
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hydrogel lenses
Number of subjects: 6
Study: 7307478

Group type: EXPERIMENTAL
Intervention: Social skills training for 10 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Holistic health therapy plus family therapy for 10 weeks
Number of subjects: 28
Study: 29627312

Group type: EXPERIMENTAL
Intervention: Heliox (79:21) delivered via low flow nasal cannula at 2 L/min for 24 hours
Number of subjects: 104

Group type: COMPARATOR
Intervention: Air delivered via nasal cannula at 2 L/min for 24 hours
Number of subjects: 104
Study: 28634710

Group type: EXPERIMENTAL
Intervention: Vuse Solo (14 to 36 mg nicotine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vuse Solo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combustible cigarettes
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 45
Study: 25370595

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 32 mg/day orally for 7 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 23163959

Group type: EXPERIMENTAL
Intervention: Olopatadine (5 mg b.i.d.)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Levocetirizine (5 mg/day)
Number of subjects: 120
Study: 21658525

Group type: EXPERIMENTAL
Intervention: History of traumatic event exposure
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nonexposed individuals
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Traumatic event exposure
Number of subjects: 127
Study: 19455296

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination therapy (interpersonal psychotherapy plus medication)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 17198587

Group type: EXPERIMENTAL
Intervention: Carboplatin-based regimen
Number of subjects: 6478

Group type: COMPARATOR
Intervention: Cisplatin-based regimen
Number of subjects: 6478
Study: 15554350

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day for 3 months
Number of subjects: 30
Study: 11261393

Group type: EXPERIMENTAL
Intervention: Homophobic group (n = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonhomophobic group (n = 26)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 9492239

Group type: EXPERIMENTAL
Intervention: Sleep (measured by time spent awake during NREM-1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intrusive thoughts and avoidance behaviors
Number of subjects: 29
Study: 8301447

Group type: EXPERIMENTAL
Intervention: Haemophilus capsular polysaccharide‐tetanus toxoid conjugate (PRP‐T) and diphtheria‐tetanus‐pertussis (DTP) vaccines administered in a single syringe (group 1)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Haemophilus capsular polysaccharide‐tetanus toxoid conjugate (PRP‐T) and diphtheria‐tetanus‐pertussis (DTP) vaccines administered in separate syringes (group 2)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: PRP‐T vaccine (group 1)
Number of subjects: 284

Group type: COMPARATOR
Intervention: PRP‐T vaccine (group 2)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: DTP antigens (group 1)
Number of subjects: 284

Group type: COMPARATOR
Intervention: DTP antigens (group 2)
Number of subjects: 284
Study: 2928074

Group type: EXPERIMENTAL
Intervention: 500-Hz low-pass noise adaptor moving right
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6300-Hz high-pass noise adaptor moving right
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probes with velocities varying from -10 degrees to +10 degrees/sec
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Same spectral content for adaptor and probe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different spectral regions for adaptor and probe
Number of subjects: 0
Study: 4174488

Group type: EXPERIMENTAL
Intervention: Long-term anticoagulant therapy for one year
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (no long-term anticoagulant therapy)
Number of subjects: 159
Study: 380463

Group type: EXPERIMENTAL
Intervention: MR K. pneumoniae infected patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isolation techniques
Number of subjects: 66

Group type: COMPARATOR
Intervention: Other gram-negative organisms
Number of subjects: 66
Study: 31489525

Group type: EXPERIMENTAL
Intervention: Biobran/MGN-3 (250 mg/day for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30799691

Group type: EXPERIMENTAL
Intervention: Tabular fact box with numbers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fact box with numbers and icon array
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fact box with numbers, separate icon arrays, and text
Number of subjects: 120

Group type: COMPARATOR
Intervention: Widely distributed health information
Number of subjects: 120